0
Allergy and Airway: Asthma II |

Der p1 and Der p2 sIgE Curative Effect Evaluation for Specific Immunotherapy FREE TO VIEW

Peiyan Zheng
Author and Funding Information

Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A20. doi:10.1016/j.chest.2016.02.022
Text Size: A A A
Published online

SESSION TITLE: Asthma II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To evaluate the differences in clinical efficacy of SIT by the lever of specific IgE (sIgE) to Der p1 and Der p2, the main components of Dermatophagoides pteronyssinus (Der p).

METHODS: This study observed the immune indexes of 52 children patients (32 patients for SIT group and 20 patients for control group) including the serum sIgE to Der p, Der p1 and Der p2 for five periods of before SIT (Pre) and after SIT (half of year after SIT (0.5Y),1 year,2 year (2Y) and 3 year (3Y)). Evaluate its application in the clinical significance of detection and specification for SIT.

RESULTS: Compared with the control group before and after treatment sIgE levels there was no significant change, SIT for half a year, Der p, Der p1 and Der p2 once elevated serum levels of sIgE, Der p to 3 years after 0.5 years SIT sIgE levels had no significant change, and Der p1 sIgE level began to drop, until three years later Der p1 sIgE levels lower than before treatment, so that Der p1 than SIT monitoring is more sensitive in Der p, and more meaningful. Using visual analog scale score curative effect, the effective group Der p1sIgE levels had significantly lower in the treatment of 3 years later, six months increased after treatment and ineffective treatment group with no lower. Der p is positive, and Der p1 and Der p2 sIgE negative patients after SIT, the three allergens sIgE levels rising, and the curative effect is poorer, unfit to SIT.

CONCLUSIONS: After immunotherapy for Der p1 sIgE lower than Der p, therefore, Der p1 sIgE may be used as SIT monitoring indicators, Der p1 and Der p2 sIgE negative patients before treatment is not suitable to SIT.

CLINICAL IMPLICATIONS: Standardized allergen specific immunotherapy (SIT) is the world health organization (WHO) recommended only can change the allergic disease treatment, However, natural processes lack the curative effect of objective monitoring indicators.

DISCLOSURE: The following authors have nothing to disclose: Peiyan Zheng

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543